ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
8.39
-0.15 (-1.76%)
Jun 29, 2026, 3:20 PM EDT - Market open
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 28.33, with a low estimate of 25 and a high estimate of 30. The average target predicts an increase of 237.66% from the current stock price of 8.39.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $30 | Buy | Maintains | $30 | +257.57% | Jun 25, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 25, 2026 |
| Northland Securities | Northland Securities | Buy Maintains $25 | Buy | Maintains | $25 | +197.97% | Apr 15, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $30 | Buy | Reiterates | $30 | +257.57% | Apr 14, 2026 |
| Raymond James | Raymond James | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jan 9, 2026 |
Financial Forecast
Revenue This Year
141.76M
from 84.28M
Increased by 68.20%
Revenue Next Year
258.78M
from 141.76M
Increased by 82.55%
EPS This Year
-1.65
from -1.74
EPS Next Year
-0.83
from -1.65
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 158.0M | 312.0M | |
| Avg | 141.8M | 258.8M | |
| Low | 127.7M | 224.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 87.5% | 120.1% | |
| Avg | 68.2% | 82.5% | |
| Low | 51.6% | 58.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.27 | -0.40 | |
| Avg | -1.65 | -0.83 | |
| Low | -2.05 | -1.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.